Merck CEO hints at $10B-plus for consumer unit; Bayer wins Euro nod for PAH med Adempas; GSK buys out Indonesia partner;

@FiercePharma: Top-read over the weekend - two special reports: The 10 best-selling drugs of 2013. Report. and The top 10 pharma companies by 2013 revenue. Report | Follow @FiercePharma

@TracyStaton: RT: Today is the first time in my 10 year data that larger cap biotech is trading at the same PE as US. | Follow @TracyStaton

@EricPFierce: FDA 's Woodcock throws cold water on research that found foreign-made generics of Lipitor tainted. Article | Follow @EricPFierce

@CarlyHFierce: Regeneron clears roadblock for new plant in Irish tax haven. Story | Follow @CarlyHFierce

> Merck ($MRK) CEO Kenneth Frazier said he's seen "substantial" interest in the consumer unit he put on the block, at "higher numbers" than $10 billion. Report

> Bayer nabbed European approval for its lung drug Adempas (riociguat) to treat pulmonary arterial hypertension (PAH) and chronic-thromboembolic hypertension; analysts see total peak sales of more than €500 million ($688 million). Report

> GlaxoSmithKline ($GSK) amped up again in emerging markets by taking full control of its consumer health unit in Indonesia; it's the British drugmaker's third recent buyout of local investors in emerging markets. Report

> European regulators green-lighted a new schizophrenia drug, Latuda, from Japan-based Takeda Pharmaceutical and Dainippon Sumitomo Pharma. Report

> Japanese watchdogs approved two flu vaccines from domestic drugmaker Takeda Pharmaceutical. Report

Medical Device News

@FierceMedDev: Abbott gained approval for a new PAD stent it acquired last July in a $310M M&A deal. Item | Follow @FierceMedDev

@MarkHFierce: Johnson & Johnson has agreed to sell its Ortho Clinical Diagnostics arm to Carlyle for more than $4B. Story | Follow @MarkHFierce

@MichaelGFierce: ICYMI: NeuroSigma brings on two Amgen execs to bolster its finance team. Item | Follow @MichaelGFierce

@EmilyWFierce: In a regulatory overhaul, Chinese authorities pass new rules governing medical devices. News | Follow @EmilyWFierce

> Medtronic commits to renal denervation as company details disappointing trial results. Story

> First head-to-head trial finds Edwards' TAVR superior to Medtronic's. More

Biotech News

@FierceBiotech: Shares of Prana collapse after long-shot Alzheimer's study flops. News | Follow @FierceBiotech

@JohnCFierce: GlaxoSmithKline's darapladib team finds hope in a PhIII bomb $GSK. Editor's Corner | Follow @JohnCFierce

@DamianFierce: In case you weren't in the mood for ACC14 this weekend, Amgen's PCSK9 drug played a starring role. More | Follow @DamianFierce

@EmilyMFierce: Ancient virus DNA gives stem cells the power to transform. Story via National Geographic | Follow @EmilyMFierce

> Amgen's PCSK9 drug slashes 'bad' cholesterol in PhIII, stoking blockbuster hopes. Article

> On the ropes, Novartis' cardiology team declares a blockbuster PhIII knockout. News

CRO News

> Icon is buying Aptiv with a focus on adaptive trials. News

> Covance dials up its biologics offerings, adding 100 new jobs. Story

> Quintiles signs on to help BioDelivery get its anti-addiction drug out the door. Story

> Rho inks a federal bioterror pact with $100M on the line. News

> NephroGenex picks Medpace for kidney disease Phase III. Story

> BioClinica bags $30M in Big Pharma deals. Brief

Biotech IT News

> GSK teams up to apply Big Data to target validation. Story

> Illumina CEO sees bioinformatics as key to completing sequencing puzzle. Article

> Report: IMS Health aiming to raise $1.4B in upcoming IPO. News

> Busy week at Intel bolsters its presence in life sciences. Story

> NIH looking to research community for data and metadata standards. Article

> Duke setting up precision medicine center in Genome Institute reshuffle. Brief

And Finally... The ancient gout drug colchicine proved effective at treating pericarditis, inflammation in the sac surrounding the heart. Report

Suggested Articles

Stephen Hahn, an oncologist who served as the chief medical officer for the MD Anderson Cancer Center, has secured Senate confirmation as FDA head.

As BMS searches for bright spots in its Opdivo-chemo combo fail from June, it’s zeroing in on squamous lung cancer patients who seemed to benefit.

The FDA's ad watchdog served its most serious violation to Alkermes Wednesday—and it took the unusual step of announcing that violation to the world.